Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives

키워드

참고문헌 (74)

1. Su TH, "Improving clinical outcomes of chronic hepatitis B virus infection", Expert Rev Gastroenterol Hepatol, 9, pp.141~154 (2015)
2. European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
3. Wieland SF, "Intrahepatic induction of alpha", beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice, 2000, pp.74, 4165~4173
4. Wieland SF, "Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids", Proc Natl Acad Sci U S A, 102, pp.9913~9917 (2005)
5. Belloni L, "IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome", J Clin Invest, 122, pp.529~537 (2012)
6. Visvanathan K, "Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein", Hepatology, 45, pp.102~110 (2007)
7. Lang T, "The hepatitis B e antigen (HBeAg) targets and suppresses activation of the Toll-like receptor signaling pathway", J Hepatol, 55, pp.762~769 (2011)
8. Op den Brouw ML, "Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus", Immunology, 126, pp.280~289 (2009)
9. Lütgehetmann M, "Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice", Gastroenterology, 140, pp.2074~2083.e2 (2011)
10. Boni C, "Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection", J Virol, 81, pp.4215~4225 (2007)
11. Das A, "Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection", J Exp Med, 205, pp.2111~2124 (2008)
12. Micco L, "Differential boosting of innateand adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B", J Hepatol, 58, pp.225~233 (2013)
13. Thimme R, "Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B", J Hepatol, 58, pp.205~209 (2013)
14. Peppa D, "Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection", PLoS Pathog, 6, pp.e1001227~ (2010)
15. Wong GL, "Combination therapy of interferon and nucleotide", nucleoside analogues for chronic hepatitis B, 2014, pp.21, 825~834
16. Mutimer D, "Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study", J Hepatol, 28, pp.923~929 (1998)
17. Barbaro G, "Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B: an Italian multicenter, randomized trial", J Hepatol, 35, pp.406~411 (2001)
18. Santantonio T, "Lamivudine", interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study, 2002, pp.36, 799~804
19. Lau GK, "Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B", N Engl J Med, 352, pp.2682~2695 (2005)
20. Janssen HL, "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial", Lancet, 365, pp.123~129 (2005)
21. Marcellin P, "Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 351, pp.1206~1217 (2004)
22. Marcellin P, "Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a", Gastroenterology, 136, pp.2169~2179.e4 (2009)
23. Werle-Lapostolle B, "Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy", Gastroenterology, 126, pp.1750~1758 (2004)
24. Wursthorn K, "Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B", Hepatology, 44, pp.675~684 (2006)
25. Piccolo P, "A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B", Antivir Ther, 14, pp.1165~1174 (2009)
26. Takkenberg RB, "Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-alpha2a and adefovir", Antivir Ther, 18, pp.895~904 (2013)
27. Marcellin P, "Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy", J Hepatol, 62, pp.41~47 (2015)
28. Marcellin P, "Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B", Gastroenterology, 150, pp.134~144.e10 (2016)
29. Enomoto M, "Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential", J Gastroenterol, 48, pp.999~1005 (2013)
30. Schalm SW, "Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial", Gut, 46, pp.562~568 (2000)
31. Chan HL, "A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone", Ann Intern Med, 142, pp.240~250 (2005)
32. Chan HL, "Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B", Hepatology, 41, pp.1357~1364 (2005)
33. Lutgehetmann M, "Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication", Antivir Ther, 13, pp.57~66 (2008)
34. Brouwer WP, "Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study)", Hepatology, 61, pp.1512~1522 (2015)
35. Li GJ, "Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment", Antimicrob Agents Chemother, 59, pp.4121~4128 (2015)
36. Bourliere M, "HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study. Multicenter randomized controlled phase III trial", J Hepatol, 62(Suppl 2), pp.S249~ (2015)
37. Liu CJ, "Entecavir plus peginteferon alfa-2a vs. entecavir alone in the treatment of hepatitis B e antigen-positive chronic hepatitis B: an interim report", J Hepatol, 58(Suppl 1), pp.S308~ (2013)
38. Huang Z, "Peginterferon-alpha2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study", Eur J Gastroenterol Hepatol, 25, pp.1165~1169 (2013)
39. Wang YX, "Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poorvirological response to peginterferon alfa", Scand J Gastroenterol, 48, pp.213~217 (2013)
40. Xie Q, "A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B “e” antigen-positive chronic hepatitis B", Clin Infect Dis, 59, pp.1714~1723 (2014)
41. Hou J, "P1067 Response-guided peginterferon alfa-2a (PegIFN alfa-2a) therapy in patients with HBeAg-positive chronic hepatitis b (CHB)", J Hepatol, 60(1 Suppl), pp.S432~S433 (2014)
42. Lampertico P, "Randomised study comparing 48 and 96 weeks peginterferon alfa-2a therapy in genotype D HBeAg-negative chronic hepatitis B", Gut, 62, pp.290~298 (2013)
43. Kumada H, "Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan", Hepatol Res, 40, pp.1~7 (2010)
44. Petersen J, "Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy", Liver Int, 35(Suppl 1), pp.114~120 (2015)
45. Boni C, "Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues", Gastroenterology, 143, pp.963~973.e9 (2012)
46. Sarin SK, "Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B", Am J Gastroenterol, 102, pp.96~104 (2007)
47. Su WW, "Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study", J Hepatol, 60(1 Suppl), pp.S47~ (2014)
48. Ning Q, "Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)", J Hepatol, 61, pp.777~784 (2014)
49. Hu P, "Predictive value of baseline and on-treatment qHBsAg level in HBeAg positive CHB patients who switched from NUCs to pegylated interferon A-2A: a further analysis from new switch study", J Hepatol, 62(Suppl 2), pp.S251~ (2015)
50. Huang Z, "Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study", J Viral Hepat, 20(Suppl 1), pp.52~57 (2013)
51. Piccolo P, "A randomized controlled trial of sequential pegylated interferon-alpha and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B", Antivir Ther, 18, pp.57~64 (2013)
52. Liaw YF, "Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review", Hepatology, 53, pp.2121~2129 (2011)
53. Tseng TC, "Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters", Gastroenterology, 141, pp.517~525.e2 (2011)
54. Tseng TC, "Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load", Hepatology, 55, pp.68~76 (2012)
55. Tseng TC, "High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load", Gastroenterology, 142, pp.1140~1149.e3 (2012)
56. Brunetto MR, "Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers", Gastroenterology, 139, pp.483~490 (2010)
57. Chan HL, "Hepatitis B surface antigen quantification: why and how to use it in 2011: a core group report", J Hepatol, 55, pp.1121~1131 (2011)
58. Brunetto MR, "Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B", Hepatology, 49, pp.1141~1150 (2009)
59. Chan HL, "Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B", Aliment Pharmacol Ther, 32, pp.1323~1331 (2010)
60. Moucari R, "Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients", Hepatology, 49, pp.1151~1157 (2009)
61. Su TH, "Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B", Antivir Ther, 15, pp.1133~1139 (2010)
62. Chan HL, "A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B", Hepatology, 52, pp.1232~1241 (2010)
63. Nguyen T, "Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia", J Hepatol, 52, pp.508~513 (2010)
64. Jaroszewicz J, "Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective", J Hepatol, 52, pp.514~522 (2010)
65. Fried MW, "HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B", Hepatology, 47, pp.428~434 (2008)
66. Zhang X, "An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients", J Viral Hepat, 18, pp.e184~e190 (2011)
67. Chan HL, "Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.", Clin Gastroenterol Hepatol, 5, pp.1462~1468 (2007)
68. Yuan Q, "Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients", Gut, 62, pp.182~184 (2013)
69. Yang HC, "Looking into the crystal ball: biomarkers for outcomes of HBV infection", Hepatol Int, 10, pp.99~101 (2016)
70. Tan AT, "Reduction of HBV replication prolongs the early immunological response to IFNalpha therapy", J Hepatol, 60, pp.54~61 (2014)
71. Lucifora J, "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA", Science, 343, pp.1221~1228 (2014)
72. Liu CJ, "Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study", Hepatology, 43, pp.742~749 (2006)
73. Lin CL, "Hepatitis B virus: new therapeutic perspectives", Liver Int, 36(Suppl 1), pp.85~92 (2016)
74. Volz T, "The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus", J Hepatol, 58, pp.861~867 (2013)

관련 논문AI추천